Sugi Predict

Sugi Predict / Compounds / SCHEMBL2431695

SCHEMBL2431695

SCHEMBL2431695

NC1CCN(C(=O)C2CC2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.60
▸ CHRNB2 P17787 4/20 0.56
▸ CHRNA3 P32297 4/20 0.56
▸ CHRNA4 P43681 4/20 0.56
▸ CHRNB3 Q05901 3/20 0.56
▸ CHRNA6 Q15825 3/20 0.56
▸ ALDH1A1 P00352 4/20 0.54
▸ TSHR P16473 1/20 0.54
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ SMYD3 Q9H7B4 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ CHRNB4 P30926 1/20 0.42
▸ CHRNA7 P36544 1/20 0.42
▸ GNAI3 P08754 1/20 0.42
▸ GNAO1 P09471 1/20 0.42
▸ GNAI1 P63096 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ HSD11B1 P28845 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27080322 0.98 HPGD (0.58) HPGDCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL18433296 0.91 ALDH1A1 (0.68) HPGDCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL27082362 0.91 ALDH1A1 (0.61) HPGDCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL2688841 0.91 ALDH1A1 (0.60) HPGDCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL25027120 0.90 HPGD (0.50) HPGDCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL27081262 0.89 ALDH1A1 (0.72) HPGDALDH1A1TSHRSMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL27080914 0.89 ALDH1A1 (0.59) HPGDCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL8226164 0.88 LMNA (0.49) HPGDCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL8518590 0.87 HPGD (0.52) HPGDCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL5102657 0.87 HPGD (0.52) HPGDCHRNB2CHRNA3CHRNA4CHRNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445501-B2 Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines TAKEDA GMBH (DE) 2013-05-21 — — US claimed
EP-2247594-A1 PYRROLOPYRIMIDINECARBOXAMIDES Nycomed GmbH (DE) 2010-11-10 — — EP claimed
WO-2009106531-A1 PYRROLOPYRIMIDINECARBOXAMIDES NYCOMED GMBH (DE) 2009-09-03 — — WO claimed
EP-4169575-B1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMA (JP) 2026-01-07 — — EP disclosed
US-12486222-B2 Compounds as soluble epoxide hydrolase inhibitors UNIVERSITAT DE BARCELONA (ES) 2025-12-02 — — US disclosed
CN-115667259-B Fused ring compounds for inhibiting H-PGDS 佐藤制药株式会社 2025-06-17 — — CN disclosed
US-20250115548-A1 COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS UNIV BARCELONA (ES) 2025-04-10 — — US disclosed
US-20240246964-A1 SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-25 — — US disclosed
US-20240182406-A1 COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS UNIVERSITAT DE BARCELONA (ES) 2024-06-06 — — US disclosed
CN-118019728-A Compounds as soluble epoxide hydrolase inhibitors 巴塞罗那大学 2024-05-10 — — CN disclosed
EP-3532474-B1 4,5-ANNULATED 1,2,4-TRIAZOLONES BAYER AG (DE) 2024-03-27 — — EP disclosed
EP-2247594-A1 PYRROLOPYRIMIDINECARBOXAMIDES Nycomed GmbH (DE) 2010-11-10 — — EP disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 — — US disclosed
WO-2010038465-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2010-04-08 — — WO disclosed
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-26 — — US disclosed
WO-2009106531-A1 PYRROLOPYRIMIDINECARBOXAMIDES NYCOMED GMBH (DE) 2009-09-03 — — WO disclosed
WO-2009067547-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 — — WO disclosed
EP-1343503-B1 HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS SCHERING CORP (US) 2008-11-12 — — EP disclosed
US-7332509-B2 Heterocyclic amides, a process for their preparation, compositions comprising them and their use MERIAL LIMITED (US) 2008-02-19 — — US disclosed
US-7332509-B2 Heterocyclic amides, a process for their preparation, compositions comprising them and their use MERIAL LIMITED (US) 2008-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182406-A1 COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, LTA4H HPGD 40/4885CHRNB2 3586/4885CHRNA3 3990/4885
US-20250115548-A1 COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, LTA4H HPGD 40/4885CHRNB2 3586/4885CHRNA3 3990/4885
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS PLK1, PLK2, POLK HPGD 2281/4885CHRNB2 4301/4885CHRNA3 4587/4885
US-12486222-B2 Compounds as soluble epoxide hydrolase inhibitors EPHX1, EPHX2, LTA4H HPGD 40/4885CHRNB2 3586/4885CHRNA3 3990/4885
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 HPGD 1893/4885CHRNB2 3479/4885CHRNA3 2886/4885
US-20240246964-A1 SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME HAVCR2, HDGF, HCCS HPGD 836/4885CHRNB2 4876/4885CHRNA3 4841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.